Dr. Daniel Claassen
Claim this profileVanderbilt University Medical Center
Area of expertise
Huntington's Disease
Daniel Claassen has run 5 trials for Huntington's Disease. Some of their research focus areas include:
Parkinson's Disease
Daniel Claassen has run 2 trials for Parkinson's Disease.
Affiliated Hospitals
Vanderbilt University Medical Center
Vanderbilt University School Of Medicine
Clinical Trials Daniel Claassen is currently running
Brain Structure Assessment
for Juvenile-onset Huntington's Disease
The goal of this observational study is to learn about brain development in Juvenile-onset Huntington's Disease (JoHD). The main questions it aims to answer are: * Is brain development different in JoHD than Adult-onset Huntington's Disease (AoHD)? * Can reliable biomarkers for JoHD be found in brain structure and function? Participants will be asked to complete cognitive tests, behavioral assessments, physical and neurologic evaluation, and MRI. Data collected will be compared to populations who are at-risk for HD and who have been diagnosed with HD as adults.
Recruiting
1 award
N/A
2 criteria
Neurodevelopment
for Huntington's Disease
Huntington's Disease (HD) is an autosomal dominant disease manifested in a triad of cognitive, psychiatric, and motor signs and symptoms. HD is caused by a triplet repeat (CAG)expansion in the gene Huntingtin (HTT). This disease has classically been conceptualized as a neurodegenerative disease. However, recent evidence suggests that abnormal brain development may play an important role in the etiology of HD. Huntingtin (HTT)is expressed during development and through life. In animal studies, the HTT gene has been shown to be vital for brain development. This suggests that a mutant form of HTT (gene-expanded or CAG repeats of 40 and above) would affect normal brain development. In addition, studies in adults who are gene-expanded for HD, but have not yet manifested the illness, (pre-HD subjects) have significant changes in the structure of their brain, even up to 20 years before onset of clinical diagnosis. How far back these changes are evident is unknown. One possibility is that these brain changes are present throughout life, due to changes in brain development,though initially associated with only subtle functional abnormalities. In an effort to better understand the developmental aspects of this brain disease, the current study proposes to evaluate brain structure and function in children, adolescents, and young adults (ages 6-30) who are at risk for developing HD - those who have a parent or grandparent with HD. Brain structure will be evaluating using Magnetic Resonance Imaging (MRI) with quantitative measures of the entire brain, cerebral cortex, as well as white matter integrity via Diffusion Tensor Imaging. Brain function will be assessed by cognitive tests, behavioral assessment, and physical and neurologic evaluation. Subjects that are gene-expanded (GE) will be compared to subjects who are gene non-expanded (GNE). Changes in brain structure and/or function in the GE group compared to the GNE group would lend support to the notion that this disease has an important developmental component.
Recruiting
1 award
N/A
3 criteria
More about Daniel Claassen
Clinical Trial Related
2 years of experience running clinical trials · Led 8 trials as a Principal Investigator · 3 Active Clinical Trials
Treatments Daniel Claassen has experience with
- Observational Study
- Meditation
- MRI Methods For Visualizing Hemodynamic And Metabolic Relationships
- AMT-130
- Imitation (sham) Surgery
- Skin Biopsy
Breakdown of trials Daniel Claassen has run
Huntington's Disease
Parkinson's Disease
Neurodegenerative Diseases
Multi-System Atrophy
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Daniel Claassen specialize in?
Daniel Claassen focuses on Huntington's Disease and Parkinson's Disease. In particular, much of their work with Huntington's Disease has involved CAG repeat length positive patients, or patients who are HTT positive.
Is Daniel Claassen currently recruiting for clinical trials?
Yes, Daniel Claassen is currently recruiting for 3 clinical trials in Nashville Tennessee. If you're interested in participating, you should apply.
Are there any treatments that Daniel Claassen has studied deeply?
Yes, Daniel Claassen has studied treatments such as Observational Study, Meditation, MRI Methods for Visualizing Hemodynamic and Metabolic Relationships.
What is the best way to schedule an appointment with Daniel Claassen?
Apply for one of the trials that Daniel Claassen is conducting.
What is the office address of Daniel Claassen?
The office of Daniel Claassen is located at: Vanderbilt University Medical Center, Nashville, Tennessee 37232 United States. This is the address for their practice at the Vanderbilt University Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.